Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2025 07:55 ET | Source: Alumis Inc.

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis
May 28, 2025 09:20 ET | Source: Research and Markets

Vitiligo Market Growth Trends and Forecast Report 2025-2033 - Rising Awareness, Diagnostic Advances, Innovative Therapies, and Expanding Global Healthcare Access

Dublin, May 28, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering.The...
May 16, 2025 06:05 ET | Source: Research and Markets

Photodynamic Therapy Market Trends Report 2025-2033:: Advancements in Light Delivery and Photosensitizers, Expanding Applications in Oncology, Dermatology, and Ophthalmology

Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Photodynamic Therapy Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's...
May 13, 2025 08:00 ET | Source: Mindera Health

Mindera Health™ announces publication of randomized, prospective clinical utility study demonstrating improved psoriasis patient outcomes

Vista, CA, May 13, 2025 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced positive results from the completion of a randomized,...
April 14, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight

New York, USA, April 14, 2025 (GLOBE NEWSWIRE) -- Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight The psoriasis pipeline possesses some drugs in...
March 25, 2025 02:30 ET | Source: Alumis Inc.

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan
March 19, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
March 12, 2025 09:00 ET | Source: SNS Insider pvt ltd

Psoriasis Treatment Market Size to Hit USD 54.40 Billion by 2032 Driven by Advances in Biologic and Innovative Therapies – SNS Insider

Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Psoriasis Treatment Market Overview: According to SNS Insider, The Psoriasis Treatment Market was worth USD 22.38 billion in 2023, is projected to grow to...
March 08, 2025 09:00 ET | Source: Alumis Inc.

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025
February 28, 2025 09:08 ET | Source: Alumis Inc.

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026

Next Page keyboard_arrow_right